Analysis of serum and plasma identifies differences in molecular coverage, measurement variability, and candidate biomarker selection

Proteomics - Clinical Applications

Volumn 6, Issue 5-6, 2012, Pages 297-303

  Alsaif, Murtada ^a   Guest, Paul C ^a   Schwarz, Emanuel ^a   Reif, Andreas ^b   Kittel Schneider, Sarah ^b   Spain, Michael ^c   Rahmoune, Hassan ^a   Bahn, Sabine ^a,d  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c Rules Based Medicine   (United States)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Measurement variability; Multiplex immunoassay; Plasma; Serum

Indexed keywords

ALPHA 2 MACROGLOBULIN; BINDING PROTEIN; BIOLOGICAL MARKER; BRAIN DERIVED NEUROTROPHIC FACTOR; C REACTIVE PROTEIN; COPPER ZINC SUPEROXIDE DISMUTASE; CORTICOTROPIN; HYDROCORTISONE; INTERSTITIAL COLLAGENASE; LIPOPROTEIN A; MATRILYSIN; METALLOPROTEINASE; PLATELET DERIVED GROWTH FACTOR BB; PROINSULIN; PROTEIN S100B; RAGE BINDING PROTEIN; SOMATOMEDIN C; STROMELYSIN 2; TRANSFERRIN; UNCLASSIFIED DRUG;

ADULT; AMINO ACID SEQUENCE; ANALYTICAL PARAMETERS; ARTICLE; BIPOLAR DISORDER; BLOOD ANALYSIS; BODY FLUID; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HUMAN; IMMUNOASSAY; INDIVIDUALITY; LIMIT OF DETECTION; MALE; MULTIPLEXED IMMUNOASSAY ANALYSIS; NUCLEOTIDE SEQUENCE; OUTCOME ASSESSMENT; PLASMA; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FOLDING; PROTEIN PLASMA LEVEL; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; SERUM;

ADOLESCENT; ADULT; BIOLOGICAL MARKERS; FEMALE; HUMANS; MALE; MIDDLE AGED; PLASMA; PROTEOMICS; SERUM;

EID: 84863207474     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100061     Document Type: Article

References (25)

1. Surhone, L., Tennoe, M., Henssonow, S., Blood Plasma, VDM Verlag Dr. Mueller AG & Co. KG, Germany 2010.
2. Chornoguz, O., Grmai, L., Sinha, P., Artemenko, K. et al., Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis. Mol. Cell Proteomics 2010, 10, M110.002980.
3. Han, C.-L., Chen, J.-S., Chan, E.-C., Wu, C.-P. et al., An informatics-assisted label-free approach for personalized tissue membrane proteomics: case study on colorectal cancer. Mol. Cell. Proteomics 2011, 10, M110.003087.
4. Issaq, H. J., Xiao, Z., Veenstra, T. D., Serum and plasma proteomics. Chem. Rev. 2007, 107, 3601-3620.
5. Anderson, N. L., Anderson, N. G., The human plasma proteome: history, character, and diagnostic prospects. Mol. Cell Proteomics 2002, 1, 845-867.
6. Haab, B. B., Geierstanger, B. H., Michailidis, G., Vitzthum, F. et al., Immunoassay and antibody microarray analysis of the HUPO Plasma Proteome Project reference specimens: systematic variation between sample types and calibration of mass spectrometry data. Proteomics 2005, 5, 3278-3291.
7. Schwarz, E., Guest, P. C., Rahmoune, H., Harris, L. W. et al., Identification of a biological signature for schizophrenia in serum. Mol. Psychiatry 2011, doi:10.1038/mp.2011.60 [Ahead of print].
8. Welsh, B. T., Mapes, J., An Overview of Assay Quality Systems at Rules-Based Medicine®. Austin, TX 2010. Available at
9. Schwarz, E., Izmailov, R., Spain, M., Barnes, A. et al., Validation of a blood-based laboratory test to aid in the confirmation of a diagnosis of schizophrenia. Biomark. Insights 2010, 2012, 39-47.
10. Bertenshaw, G. P., Yip, P., Seshaiah, P., Zhao, J. et al., Multianalyte profiling of serum antigens and autoimmune and infectious disease molecules to identify biomarkers dysregulated in epithelial ovarian cancer. Cancer Epidemiol. Biomark. Prev. 2008, 17, 2872-2881.
11. Trajkovska, V., Marcussen, A., Vinberg, M., Hartvig, P., et al. Measurements of brain-derived neurotrophic factor: methodological aspects and demographical data. Brain Res. Bull. 2007, 73, 143-149.
12. Wan, C., La, Y., Zhu, H., Yang, Y. et al., Abnormal changes of plasma acute phase proteins in schizophrenia and the relation between schizophrenia and haptoglobin (Hp) gene. Amino Acids 2007, 32, 101-108.
13. Gershtein, E., Levkina, N., Digayeva, M., Laktionov, N. et al., Matrix metalloproteinases 2, 7, and 9 and tissue inhibitor of metalloproteinases-1 in tumors and serum of patients with ovarian neoplasms. Bull. Exp. Biol. Med. 2010, 149, 628-631.
14. Karihtala, P., Mäenpää, J., Turpeenniemi-Hujanen, T., Puistola, U., Front-line Bevacizumab in serous epithelial ovarian cancer: biomarker analysis of the FINAVAST trial. Anticancer Res. 2010, 30, 1001-1006.
15. Mahner, S., Woelber, L., Eulenburg, C., Schwarz, J. et al., TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. BMC Cancer 2010, 10, 139.
16. Stettner, R., Bogusiewicz, M., Rechberger, T., Matrix metalloproteinases and their inhibitors in ovarian cancer progression-diagnostic and therapeutic implications. Ginekol. Pol. 2009, 80, 47-53.
17. Rauvala, M., Turpeenniemi-Hujanen, T., Puistola, U., The value of sequential serum measurements of gelatinases and tissue inhibitors during chemotherapy in ovarian cancer. Anticancer Res. 2006, 26, 4779-4784.
18. Rauvala, M., Puistola, U., Turpeenniemi-Hujanen, T., Gelatinases and their tissue inhibitors in ovarian tumors; TIMP-1 is a predictive as well as a prognostic factor. Gynecol. Oncol. 2005, 99, 656-663.
19. Manenti, L., Paganoni, P., Floriani, I., Landoni, F. et al., Expression levels of vascular endothelial growth factor, matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 and 2 in the plasma of patients with ovarian carcinoma. Eur. J. Cancer 2003, 39, 1948-1956.
20. Dodig, S., Interferences in quantitative immunochemical methods. Biochem. Med. 2009, 19, 50-62.
21. Van Wart, H., Birkedal-Hansen, H., The cysteine switch: a principle of regulation of metalloproteinase activity with potential applicability to the entire matrix metalloproteinase gene family. PNAS 1990, 87, 5578-5582.
22. Creemers, J., Jackson, R., Hutton, J., Molecular and cellular regulation of prohormone processing. Semin. Cell Dev. Biol. 1998, 9, 3-10.
23. Zweig, M., Glickman, J., Csako, G., Analytical interference caused by incompletely clotted serum specimens. Clin. Chem. 1994, 40, 2325-2326.
24. Chang, C., Lu, J., Chien, T., Kao, J. et al., Interference caused by the contents of serum separator tubes in the vitros CRP assay. Ann. Clin. Biochem. 2003, 40, 249-251.
25. Omenn, G. S., States, D. J., Adamski, M., Blackwell, T. W. et al., Overview of the HUPO plasma proteome project: results from the pilot phase with 35 collaborating laboratories and multiple analytical groups, generating a core dataset of 3020 proteins and a publicly-available database. Proteomics 2005, 5, 3226-3245.